These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9162756)

  • 1. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
    Morand OH; Aebi JD; Dehmlow H; Ji YH; Gains N; Lengsfeld H; Himber J
    J Lipid Res; 1997 Feb; 38(2):373-90. PubMed ID: 9162756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4'-(6-allyl-ethyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin.
    Peffley DM; Gayen AK; Morand OH
    Biochem Pharmacol; 1998 Aug; 56(4):439-49. PubMed ID: 9763219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.
    Mark M; Muller P; Maier R; Eisele B
    J Lipid Res; 1996 Jan; 37(1):148-58. PubMed ID: 8820110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a 2,3-oxidosqualene-lanosterol cyclase inhibitor 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line HepG2.
    Dollis D; Schuber F
    Biochem Pharmacol; 1994 Jul; 48(1):49-57. PubMed ID: 8043030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.
    Telford DE; Lipson SM; Barrett PH; Sutherland BG; Edwards JY; Aebi JD; Dehmlow H; Morand OH; Huff MW
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2608-14. PubMed ID: 16210564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo.
    Eisele B; Budzinski R; Müller P; Maier R; Mark M
    J Lipid Res; 1997 Mar; 38(3):564-75. PubMed ID: 9101437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
    Burton PM; Swinney DC; Heller R; Dunlap B; Chiou M; Malonzo E; Haller J; Walker KA; Salari A; Murakami S
    Biochem Pharmacol; 1995 Aug; 50(4):529-44. PubMed ID: 7646560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase.
    Thoma R; Schulz-Gasch T; D'Arcy B; Benz J; Aebi J; Dehmlow H; Hennig M; Stihle M; Ruf A
    Nature; 2004 Nov; 432(7013):118-22. PubMed ID: 15525992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of CYP3A by 2,3-oxidosqualene:lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes.
    Shenoy SD; Spencer TA; Mercer-Haines NA; Abdolalipour M; Wurster WL; Runge-Morris M; Kocarek TA
    Mol Pharmacol; 2004 May; 65(5):1302-12. PubMed ID: 15102959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse.
    Chuang JC; Valasek MA; Lopez AM; Posey KS; Repa JJ; Turley SD
    Biochem Pharmacol; 2014 Apr; 88(3):351-63. PubMed ID: 24486573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
    Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
    J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.
    Rowe AH; Argmann CA; Edwards JY; Sawyez CG; Morand OH; Hegele RA; Huff MW
    Circ Res; 2003 Oct; 93(8):717-25. PubMed ID: 14512442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear.
    Huff MW; Telford DE
    Trends Pharmacol Sci; 2005 Jul; 26(7):335-40. PubMed ID: 15951028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.
    Liang Y; Besch-Williford C; Aebi JD; Mafuvadze B; Cook MT; Zou X; Hyder SM
    Breast Cancer Res Treat; 2014 Jul; 146(1):51-62. PubMed ID: 24878988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells.
    Sawada M; Matsuo M; Hagihara H; Tenda N; Nagayoshi A; Okumura H; Washizuka K; Seki J; Goto T
    Eur J Pharmacol; 2001 Nov; 431(1):11-6. PubMed ID: 11716837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.